Naval G. Daver, MD, oncologist, Department of Leukemia, The University of Texas MD Anderson Cancer Center, discusses the role of minimal residual disease (MRD) assessment in the treatment of patients with hematologic malignancies. Daver says MRD has emerged as an important part of predicting outcomes in these patients compared to previous standards in this setting.
